Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356631 | 0.87 | TP53 (0.70) | LMNASMN1; SMN2PKMTP53MAPT | |
| SCHEMBL1355051 | 0.84 | ALDH1A1 (0.70) | LMNASMN1; SMN2KMT2AMAPTALDH1A1 | |
| SCHEMBL6278367 | 0.83 | ALDH1A1 (0.73) | LMNAKMT2AMAPTALDH1A1POLB | |
| SCHEMBL962893 | 0.81 | LMNA (0.74) | LMNASMN1; SMN2KMT2AHTTALDH1A1 | |
| SCHEMBL2180527 | 0.81 | LMNA (0.54) | LMNAPKMKMT2ATP53MAPT | |
| SCHEMBL1353584 | 0.74 | LMNA (0.61) | LMNASMN1; SMN2KMT2ATP53ALDH1A1 | |
| SCHEMBL2181549 | 0.73 | CACNA1G (0.51) | LMNAKMT2AALDH1A1POLBCA1 | |
| SCHEMBL16809207 | 0.73 | SIGMAR1 (0.56) | SMN1; SMN2PKMMAPTHTTALDH1A1 | |
| SCHEMBL14006292 | 0.73 | HDAC3 (0.58) | SMN1; SMN2MAPTL3MBTL1ALDH1A1POLB | |
| SCHEMBL2477809 | 0.72 | HRH3 (0.71) | LMNASMN1; SMN2KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| US-6861432-B2 | Piperazine derivatives that destabilize androgen receptors | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| EP-1301497-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004434-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | TOP1, TDP1, TOP2B | LMNA 88/4885SMN1; SMN2 1443/4885PKM 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.